Get to know our clinical trials
Study to evaluate the effect of balcinrenone/dapagliflozin in patients with heart failure and impaired renal function (BalanceD-HF).
THE MAIN OBJECTIVE IS TO EVALUATE THE EFFECT OF BALCINRENONE/DAPAGLIFLOZIN VERSUS DAPAGLIFLOZIN, ADMINISTERED ONCE DAILY IN ADDITION TO OTHER SOC CLASSES, ON CV DEATH AND HEART FAILURE EVENTS.
Status
In recruitment
headquarters
Pamplona/Madrid
Technical Summary
- BALANCED-HF: PHASE III, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE EFFECT OF BALCINRENONE/DAPAGLIFLOZIN, COMPARED WITH DAPAGLIFLOZIN, ON THE RISK OF HEART FAILURE EVENTS AND CARDIOVASCULAR DEATH IN PATIENTS WITH HEART FAILURE AND IMPAIRED RENAL FUNCTION.
- Code EudraCT: 2023-508162-15-00
- Protocol number: D6402C00012
- Promoter: Astra Zeneca AB
- Molecule/Drug: balcinrenona/dapagliflozina
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.